Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts

Journal of Nuclear Medicine

Volumn 37, Issue 1, 1996, Pages 38-41

  De Klerk, John M H ^a   Van Dieren, Erik B ^b   Van Het Schip, Alfred D ^b   Hoekstra, Anne ^b   Zonnenberg, Bernard A ^b   Van Dijk, Aalt ^b   Rutgers, Derk H ^b   Blijham, Geert H ^b   Van Rijk, Peter P ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

bone metastases; dosimetry; rhenium 186 HEDP; toxicity

Indexed keywords

ETIDRONIC ACID RE 186;

ADULT; AGED; ARTICLE; BONE MARROW; BONE METASTASIS; BONE PAIN; CLINICAL ARTICLE; DOSIMETRY; DRUG ABSORPTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOISOTOPE THERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED; BONE MARROW; BONE NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; ETIDRONIC ACID; HUMANS; MALE; PALLIATIVE CARE; PLATELET COUNT; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOISOTOPES; RHENIUM; THROMBOCYTOPENIA;

EID: 0029886493     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Vissers O, Coebergh JWW, Schouten LJ, eds. Incidence of cancer in The Netherlands. Second report of The Netherlands cancer registry Copenhagen. The Netherlands Cancer Registry; 1990.
2. Hoskin PJ. Palliation of bone metastases. Eur J Cancer 1991,27.950-951.
3. Scher HI, Yagoda A. Bone metastases: pathogenesis, treatment and rationale for use of resorption inhibitors Am J Med 1987;82(suppl 2A):6-28
4. Hoskin PJ. Radiotherapy in the management of bone metastases. Ln: Rubens RD. Fogelman I, eds Bone metastases. diagnosis and treatment London. Springer-Verlag; 1991:171-185
5. Poulsen HS, Nielsen OS, Klee M, Rorth M Palliative irradiation of bone metastases. Cancer Treat Rev 1989;16 41-48.
6. Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993;20:66-74
7. Ackery D, Yardly J Radionuclide-targeted therapy for the management of metastatic bone pain. Semin Oncol 1993;20:27-31.
8. Maxon HR, Deutsch EA, Thomas SR, et al Rhenium-186(Sn)HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 1988;166.501-507.
9. Maxon HR, Schroder LE, Thomas SR, et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer Radiology 1990;176:155-159
10. de Klerk JMH, Zonnenberg BA, van Rijk PP, et al Treatment of metastatic bone pain in patients with breast or prostate cancer with Re-186-MEDP Preliminary results [Abstract] Eur J Nucl Med 1991;18.528
11. Maxon HR, Schroder LE, Hertzberg VS, et al Rhenium-186(Sn)HEDP for treatment of painful osseous metastases. results of a double-blind crossover comparison with placebo. J Nucl Med 1991;32:1877-1881.
12. de Klerk JMH, Zonnenberg BA, van het Schip AD, et al Dose escalation study of rhenium-186-hydroxyethylidene diphosphonate in patients with metastatic prostate cancer Eur J Nucl Med 1994,21:1121-1125.
13. Loevinger R, Berman M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides MIRD Pamphlet no 1, revised New York: The Society of Nuclear Medicine, 1976
14. Johnson J, Langhorst SM, Loyalka K, Volkert WA, Ketring AR. Calculation of radiation dose at a bone-to-marrow interface using monte carlo modeling techniques (EGS4). J Nucl Med 1992;33:623-628
15. de Klerk JMH, van het Schip AD, Zonnenberg BA, et al. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP. guidelines for individual dosage recommendations J Nucl Med 1994,35:1423-1428
16. de Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP Pharmacokinetics of rhenium-186-HEDP after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992;33.646-651.
17. van het Schip AD, de Klerk JMH, van Dijk A, Zonnenberg BA, van Rijk PP. Pharmacokinetics of Re-186-HEDP: comparison of two formulations in patients with bone metastases [Abstract]. Eur J Nucl Med 1993;20:876
18. Spiers FW, Beddoe AH, Whitwell JR. Mean skeletal dose factors for beta-particle emitters in human bone. Part I: volume-seeking radionuclides. Br J Rad 1978;51:622-627.
19. Eckerman KF. Aspects of the dosimetry of radionuclides within the skeleton with particular emphasis on the active marrow. In: Schlafke-Stelson AT, Watson EE, eds. Proceedings of the Fourth International radiopharmaceutical and dosimetry symposium Oak Ridge, TN: Oak Ridge Associated Universities; CONF-851113; 1986:514-534.
20. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibod Immunoconj Radiopharm 1990;3:213-233.
21. Cloutier RJ, Watson EE Radiation dose from radioisotopes in the blood. In: Cloutier RJ, Edwards CI, Snyder WS, eds Medical radionuclides. radiation dose and effects. AEC symposium series no. 20 Oak Ridge, TN: Oak Ridge Associated Universities, CONF 691212; 1970:325-346
22. Heggie JCP. Radiation absorbed dose calculation for samarium-153-EDTMP localized in bone. J Nucl Med 1991;32:840-844.
23. ICRP-38. Radionuclide transformation energy and intensity of emissions. Oxford: Permagon Press, 1983
24. Watson EE, Stabin M. Basic alternatives software package for internal radiation dose calculations. In: Kathren RL, Higby DP, McKinney MA, eds. Computer applications in health physics Proceedings of the 17th midyear topical symposium of the Health Physics Society. Richland. WA: Columbia Chapter, HPS 1984;4.49-4.58.
25. Plaizier MABD, Roos JC, Teule GJJ, et al. Comparison of noninvasive appproaches to red marrow dosimetry for radiolabelled monoclonal antibodies. Eur J Nucl Med 1994;21-216-222.
26. ICRP ICRP 23 Report of the task group on reference man. Oxford: Pergamon Press: 1975.
27. ICRP. ICRP 30 Limits for intakes of radionuclides by workers Oxford Permagon Press: 1975.
28. Holford NHG, Sheiner LB. Understanding the dose-effect relationship. clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharma 1981,6:429-453.
29. Humm JL, Macklis RM, Bump K, Cobb LM, Chin LM Internal dosimetry using data derived from autoradiographs J Nucl Med 1993;34.1811-1817.
30. Makrigiorgos GM, Adelstein SJ, Kassis AI Limitations of conventional internal dosimetry at the cellular level. J Nucl Med 1989;30-1856-1864.
31. van Dieren EB, van Lingen A, Roos JC, Teule GJJ. The application of the distance histogram technique in microdosimetry for evaluating heterogeneity. In: Watson EE, Schlafke-Stelson AT, eds. Proceeding of the Fifth International Radiopharmaceutical Dosimetry Symposium Oak Ridge, TN. Oak Ridge Associated Universities: Conf. 910529, 1992:577-589.
32. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Strontium-89 therapy. strontium kinetics in disseminated carcinoma of the prostate Eur J Nucl Med 1986;12:447-454.
33. Maxon HR, Thomas SR, Hertzberg VS, et al. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med 1992,22:33-40